Riboflavin for corneal cross-linking

Area of Science:

• Ophthalmology
• Biomedical Engineering
• Corneal Science

Background:

• Keratoconus and corneal ectasias are progressive conditions affecting corneal shape and vision.
• Current treatments aim to manage symptoms, but arresting disease progression has been a significant challenge.

Purpose of the Study:

• To evaluate the efficacy of corneal collagen cross-linking (CXL) as a therapeutic intervention for keratoconus and other corneal ectasias.
• To assess the safety profile and long-term outcomes of CXL treatment.

Main Methods:

• Corneal collagen cross-linking (CXL) procedure involving topical riboflavin application followed by ultraviolet A (UVA) irradiation.
• Riboflavin acts as a photosensitizer, generating free radicals that enhance stromal biomechanical properties.
• Riboflavin also serves as a UV-blocking agent, protecting intraocular structures from potential UVA damage.

Main Results:

• Cessation of ectatic progression reported in over 90% of treated cases.
• Significant improvements observed in visual acuity, keratometric measurements, and corneal topography.
• Sustained corneal stability and shape enhancement noted in 5-10 year follow-up studies.
• Sight-threatening complications associated with CXL are rare.

Conclusions:

• Corneal collagen cross-linking (CXL) with riboflavin and UVA is a highly effective treatment for halting the progression of keratoconus and corneal ectasias.
• The procedure demonstrates a favorable safety profile and leads to significant improvements in visual and topographical outcomes.
• Further research is needed to determine the optimal stromal riboflavin dosage for CXL.